<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty-seven pregnancies in women with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) are presented </plain></SENT>
<SENT sid="1" pm="."><plain>These were treated with s.c. enoxaparin and low dose aspirin </plain></SENT>
<SENT sid="2" pm="."><plain>In fourteen pregnancies <z:chebi fb="8" ids="10033">warfarin</z:chebi> was prescribed between weeks 15-34 (<z:chebi fb="8" ids="10033">warfarin</z:chebi> group) </plain></SENT>
<SENT sid="3" pm="."><plain>The decision to switch to <z:chebi fb="8" ids="10033">warfarin</z:chebi> depended on a morbidity score, and the patient's consent </plain></SENT>
<SENT sid="4" pm="."><plain>Neither teratogenicity nor significant maternal, fetal or neonatal <z:mp ids='MP_0001914'>hemorrhage</z:mp> was observed </plain></SENT>
<SENT sid="5" pm="."><plain>Despite the higher pretreatment morbidity score of the <z:chebi fb="8" ids="10033">warfarin</z:chebi> group, the live birth rate was high in both groups: 86% in the <z:chebi fb="8" ids="10033">warfarin</z:chebi> group and 87% in the non-<z:chebi fb="8" ids="10033">warfarin</z:chebi> group </plain></SENT>
<SENT sid="6" pm="."><plain>There was no significant difference in week of delivery, birth weight, or incidence of <z:mp ids='MP_0005048'>thrombosis</z:mp> between the groups </plain></SENT>
<SENT sid="7" pm="."><plain>The study demonstrates the efficacy and safety of <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> during pregnancy </plain></SENT>
<SENT sid="8" pm="."><plain>The use of LMWH in pregnant women with APS not being moot, <z:chebi fb="8" ids="10033">warfarin</z:chebi> might be justified in selected patients </plain></SENT>
</text></document>